VENAZA-5S
An open-label, single-arm, pilot study of Venetoclax in combination with 5 days Azacitidine in treatment- naïve subjects with acute myelogenous leukemia who are ≥18 years of age and not eligible for standard induction therapy
| Studienleiter | Prof. Dr. med. Metzeler |
| EudraCT-Nr. | 2022-501537-23-00 |
| Studientyp | offene, einarmige Studie |
| Indikation | ED AML-Patienten, die für eine Standard-Induktion nicht in Frage kommen |
| ClinicalTrial | NCT05833438 |